Faxed prescriptions will only be	e accepted fro	om a prescriber. Patie	ents must bring an original	prescription to the ph	armacy, and cannot fax the	ese referral forms to	Senderra.	
G	Hemophilia Enrollment Form		Prescriber: Ni			NPI:	PI:	
			Supervising Physician: N			NPI:	NPI:	
SENDERRA Specially Pharmacy	Physician Offices Call: 855-460-7928		Address:			Tax ID:		
3712 E. Plano Parkway, Ste. 200 Plano, TX 75074	0 <b>Fax: 888-777-5645</b>		Phone: Fax:		Fax:			
This prescription form is to be sent & received via fax			Contact:					
PATIENT INFORMATION								
Name:		□ M □ F □ Trans M □ Trans F □ Other □ DOB:				SS#:		
Street:		City:		State:	<u> </u>	Zip:	· ·	
Phone:	☐ English ☐ Spanish ☐ Other:			ner:	Wt.:	Ht.:		
PRESCRIPTION								
□ New □ Refill Ship by:			TO: Patient's H	ome Doctor's	Office Other:			
Factor I (Recombinant)		□ RiaSTAP®						
Factor VIIa (Recombinant)	NovoSeven® RT Sevenfact®							
Factor VIII (Recombinant)		□ Advate® □ Adynovate® □ Afstyla® □ Eloctate <sup>™</sup> □ Esperoct <sup>®</sup> □ Jivi <sup>®</sup> □ Kogenate <sup>®</sup> FS □ Kovaltry <sup>®</sup> □ NovoEight <sup>®</sup> □ Nuwiq <sup>®</sup> □ Recombinate <sup>®</sup> □ Xyntha <sup>®</sup>						
Factor VIII (Human)		☐ Hemofil® M ☐ Monarc-M <sup>™</sup>						
Factor VIII (Human) + VWF		☐ Alphanate® SD ☐ Humate-P® ☐ Koāte® DVI ☐ Wilate®						
Factor IX (Recombinant)		☐ Alprolix® ☐ Benefix® RT ☐ Idelvion® ☐ Ixinity® ☐ Rixubis®						
Factor IX (Human)		☐ AlphaNine® S	☐ AlphaNine® SD ☐ Proplex T					
Factor X Activator (Human/Recombi	☐ Hemlibra®							
Factor XIII (Human)	□ Corifact®							
Factor XIII (Recombinant)		□ Tretten®						
Von Willebrand Factor (Recombinant)		□ Vonvendi®						
Anti-Inhibitor (Factor)	□ Feiba®							
Pro-Thrombin Complex (Human) ☐ Profilnine® SD								
Therapy Regimen for Factor or Inhibitor Products		□ Prophylaxis/week □ Breakthrough Bleed □ Immune Tolerance						
		☐ Target Dose:IU/kg ☐ Minor:IU ±				Target Dose:IU/kg		
		Dose:	IU ±%	☐ Moderate:	<del></del>	Dose:IU ±%		
		(Assay # of Doses:	(Assay Variation)     ☐ Major:     IU ±     %     (Assay Variation)       of Doses:     Refills:     # of Doses:     Refills:     # of Doses:     Refills:					
Flushing Protocol			ide 0.9% 5-10 mL pre			Units/mL	mL as needed	
Ancillary Supplies			proper administration and proper disposal of medication and infusion supplies					
Skilled Nursing Visits   As needed for IV access, administration, and proper clinical monitoring								
All nursing services requirements to be completed per pharmacy protocol								
		☐ Amicar®	Directions:			Qty:	Refills:	
Other Medications		☐ Lysteda®	Directions:			Qty:	Refills:	
Cities incurcations		☐ Stimate®	Directions:			Qty:	Refills:	
		□	Directions:			Qty:	Refills:	
MEDICAL INFORMATION								
***PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY***								
Circulating Factor:% Target Joints: No Yes Severity: Severe (<1%) Moderate (1-5%) Mild (>5%)								
Inhibitor Activity: None Historical Current BU/mL Access: Peripheral PICC Implanted Port Other:								
Protocol: Pre-surgical Prophylaxis Immune Tolerance On-demand Start date:// End date://								
Diagnosis Date:// Allergies:								
□ D66 Type A- Factor VIII Deficiency □ D67 Type B- Factor IX Deficiency □ D68.1 Type C- Factor XI Deficiency								
D68.2 Hereditary deficiency of other clotting factors  D68.32 Hemorrhagic disorder due to extrinsic circulating anticoagulants  D68.4 Acquired coagulation factor deficiency								
□ D68.0. Von Willebrand Disease (Type: □1 □ 2 □ 3) □Other:								
PRESCRIBER SIGNATURE								
To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.								
Prescriber:	J-µay assista	anoe iouniualions.		Date:	Date:			
CONFIDENTIALITY NOTICE								
CONFIDENTIALITY NOTICE  IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should								
not disseminate, distribute, or copy this fax. Please r	notify the sender	r immediately if you have	received this document in er	ror and then destroy this o	locument immediately.			

Hemophilia Enrollment Form (Rev. 11/28/2023)